Lessons from LIBRETTO-431 Trial in RET+ NSCLC
An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.
Source: ajmc.com
Libretto 431 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Libretto 431. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Libretto 431 Today - Breaking & Trending Today
Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431
Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.
Source: onclive.com
Phase 3 Study of Selpercatinib Meets Primary PFS End Point in NSCLC
Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.
Source: ajmc.com